Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
SHANGHAI, May 22, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including the Phase Ib/II clinical study data of 9MW2821 in combination with toripalimab for locally...
Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China
NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabling the company designed to initiate a pivotal clinical trial of Actair® for the treatment of house dust mite-induced allergic rhinitis...
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) Efficacy and safety of lunbotinib fumarate (A400/EP0031,宁泰莱®), a next-generation selective RET inhibitor (SRI), from a pivotal registrational Phase Ⅱ study in patients with advanced...
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI, May 22, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026,...
Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea, May 22, 2026 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms...
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) versus investigator's choice of chemotherapy as...
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng Pharmaceutical Ltd, a global clinical-stage biopharmaceutical company, announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478). Newave Pharmaceutical Inc. (hereinafter referred to...
Neurophet Appoints Globally Renowned Imaging AI Expert Dr. Lawrence N. Tanenbaum as Scientific Advisor
Former Vice President and Chief Technology Officer of RadNet, one of the largest outpatient imaging providers in the United States Appointment expected to strengthen clinical validation, global expansion, and competitiveness in neuroimaging AI SEOUL, South Korea, May 21, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an...
Origin Agritech Announces Financial Results for the First Half of Fiscal Year 2026
Net Loss Narrows by 44% Year-Over-Year, Driven by 44% Reduction in Operating Expenses BEIJING, May 21, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced its unaudited financial results for the six months ended March 31, 2026. Business Accomplishments and Highlights for the Six Months Ended March 31, 2026,...
Launch of the “Qinglan Program” in Beijing: CASWSS, Fudan Institute on Ageing and Neutech Group Jointly Build the “Hope Project” for China’s Elderly Care Industry
HONG KONG, May 21, 2026 /PRNewswire/ -- On the afternoon of May 18, 2026, the press conference of the Youth Directors Growth Accompaniment Program (referred to as the "Qinglan Program") was successfully held at the National Convention Center in Beijing. The event was jointly initiated by the China Association of Social Welfare and Senior Service (CASWSS) and Fudan Institute...
